Development and validation of a prediction model for six-month societal costs in older community care-recipients in multiple countries; the IBenC study

Lisanne van Lier (l.vanlier@amsterdamumc.nl)
Amsterdam Universitair Medische Centra https://orcid.org/0000-0001-5707-2345
Judith E Bosmans
Vrije Universiteit Amsterdam
Henriette G van der Roest
Amsterdam Universitair Medische Centra
Martyn W Heymans
Amsterdam Universitair Medische Centra
Vjenka Garms-Homolová
Hochschule Karlsruhe Technik und Wirtschaft
Anja Declercq
Katholieke Universiteit Leuven
Pálmi V Jónsson
Landspitali
Hein P.J. van Hout
Amsterdam Universitair Medische Centra

Research article

Keywords: prediction model, elderly people, societal costs, Linear Mixed Models

Posted Date: October 24th, 2019

DOI: https://doi.org/10.21203/rs.2.16402/v1

Abstract

Objectives To develop and validate a prediction model of societal costs during a period of six-month in older community care-recipients across multiple European countries.

Methods Data from the IBenC study were used. Participants were older community care-recipients from five European countries. The outcome measure was mean six-months total societal costs of resource utilisation (healthcare and informal care). Potential predictors were assessed at baseline and included sociodemographic characteristics, functional limitations, clinical conditions, and diseases/disorders. The model was developed by performing Linear Mixed Models with a random intercept for the effect of country and validated by an internal-external validation procedure. Calibration curves and expected-to-observed (E/O) ratios were calculated.

Results Living alone, caregiver distress, ADL and iADL impairment, required level of care support, health instability, presence of pain, behavioural problems, urinary incontinence, and multimorbidity significantly predicted societal costs during six months. The model explained 32% of the variation within societal costs and showed good calibration in Iceland, Finland and Germany. Minor model adaptations improved model performance in The Netherland and Italy.

Conclusion The results can provide a valuable orientation for policymakers to better understand cost development among older community care-recipients. Of the predictors that were identified, caregiver distress, ADL and IADL impairment, health instability, presence of pain, behavioural problems, and urinary incontinence may be modifiable to some extent and could be targeted by interventions with the aim to reduce costs. The other, non-modifiable predictors, including living alone, required level of care support, and multimorbidity may be used by policy makers for optimal resource allocation.

Introduction

The number of disabled older individuals in need of long-term health and social care increases steeply in Europe [1, 2]. Most of them prefer to stay at home independently for as long as possible with appropriate support instead of going to a nursing home [3]. This policy is also promoted by many European governments, as it is generally assumed that community care is associated with better self-reported quality of life and with lower costs than institutionalised care [4, 5].

Despite this, governmental expenditures on health and long-term community care have grown faster than can be expected based on demographic trends only [6]. Developments other than aging that probably contributed to this include: a decline in the availability of informal caregiving due to societal developments, higher expectations in terms of quality of life as people become wealthier, and high investments in science and technology (both medical and non-medical) that enable people to stay at home longer [2]. In combination with existing budget constraints, this has led to high pressure on care systems across Europe. Many community care systems fall short to meet current care demands. This may lead to premature institutionalisation and unnecessary hospital admissions, which in turn increases

costs, leads to premature mortality and reduces quality of life [7, 8]. This situation exacerbates as Europe is facing increasing shortages of home health aides and home nurses [9]. It is a major challenge for policymakers to organise care in such a way that available resources are used optimally.

For a comprehensive view on total costs of care, it is important to take a societal perspective on costs meaning that not only costs of health and social care should be included, but also informal care. This is important because a large percentage of community care-recipients receive informal care regularly [8, 10]. We have only limited understanding of factors predicting costs of utilisation of formal and informal care services by older community care-recipients. Previous studies on predictors of societal costs found that country of residence, being married, functional limitations, limitations of going out, cognitive impairment, number of medication intake, arthritis and cerebrovascular accident and comorbidity contributed to a large extent to societal costs [11–17]. However, these studies mainly focused on disease-specific groups such as people with dementia and not on people who receive community care in general. Since funding systems in long-term care are not designed based upon disease-specific groups, insight into the populations and the costs is essential for the sustainability of long-term care settings. Modifiable conditions that are found to be cost drivers, might be targeted more adequately in order to curtail care utilisation. Therefore, this study aimed to develop and validate a prediction model of societal costs during a period of six-months of older community care-recipients across multiple European countries.

Methods

Design

Data were collected as part of the cross-European IBenC (“Identifying best practices for care-dependent elderly by Benchmarking Costs and outcomes of community care”) study. IBenC had a prospective longitudinal design and aimed to identify best practices in community care for care-dependent elderly people by benchmarking the cost-effectiveness of community care delivery systems in Europe [18]. Data collection was performed between January 2014 and August 2016.

The study was approved by all relevant medical ethical committees. When required, written informed consent was obtained from participants prior to the assessments.

Setting and sample

The IBenC sample consisted of 2,884 community-dwelling care-recipients aged 65 years and older from six European countries (Belgium, Finland, Germany, Iceland, Italy and The Netherlands), who received professional community care and were expected to receive care for at least six months after inclusion. Terminally ill care-recipients and care-recipients with a planned admittance to a nursing home within six months after the start of the study were not included in the study.

Procedure

Community care organisations were invited to participate by the national study centres. Eligible care-recipients were invited by the care organisations or automatically enrolled, depending on the local ethical regulations. Care-recipient outcome data were collected using the interRAI Home Care (HC) instrument. Data were collected at the homes of care-recipients by trained (research) nurses, using licensed software [19]. InterRAI-HC assessments were performed at baseline, after six, and after twelve months.

Instrument

Data on care-recipient characteristics and resource utilisation were collected with the interRAI-HC. The interRAI-HC is a standardised and reliable comprehensive geriatric assessment instrument designed to assist in care planning, outcome measurement, quality improvement, and resource allocation for care-recipients who receive care at home [20–22].

Primary outcome measure

The primary outcome measure was the mean total societal costs based on resource utilisation over a six months follow-up period. Societal costs included the utilisation of community care, physician visits, other healthcare services, hospital admissions, supportive care services, number of days in institutionalised care, and informal caregiver time. Resource utilisation was registered over three, seven or 90 days prior to the assessment, depending on the type of service. The length of hospital stay in days was estimated by multiplying the reported number of events with country-specific averages of length of hospital stay during the year 2012 [23] (Table 1). For both assessments, resource utilisation was extrapolated to reflect a period of three months. Subsequently, units of resource utilisation were multiplied by Dutch standard costs in order to calculate cost of resource utilisation [24] (Table 1). Costs between measurements were linearly interpolated by multiplying costs at baseline assessment by 0.5; costs at six months after baseline by 1.5 [25]. Total costs over the period of six months were calculated by summing the extrapolated baseline and six-month cost estimates. This approach had good convergent validity as compared with the Resource Utilization in Dementia Lite instrument [25, 26], and is, therefore, considered to be valid to estimate societal costs over six months.

Predictors

Potential predictors of societal costs were derived from previous prediction and costing studies, and from what experts assumed about the interrelationship between the characteristics of older community care-recipients and societal costs [10–17]. Information on predictors was collected at baseline and included sociodemographic characteristics, functional limitations, clinical conditions, and diseases/disordersof the care-recipients. Predictors are described briefly below and described in more detail in Appendix I.

Sociodemographic characteristics included age, gender, living alone, loneliness, and caregiver distress. The interRAI-HC includes several functional scales, which were used to assess *functional limitations,* including functional impairments, difficulty in performing instrumental activities, cognitive impairment, presence of depressive symptoms, required level of formal and informal care support, health instability,

and presence of pain [26–33]. Other functional limitations that were considered, included behavioural problems and any falls. *Clinical conditions* included anxiety, dehydration, dizziness, major skin problems, pressure ulcer, unintended weight loss, and urinary incontinence.

Clinically established *diseases/disorders* included Alzheimer's disease, cancer, chronic obstructive pulmonary disease, congestive heart failure, coronary artery disease, diagnosis of urinary tract infection, dementia other than Alzheimer's disease, depression, diabetes, hemiplegia, multiple sclerosis, Parkinson's disease, pneumonia, stroke (Cardio Vascular Accident), and any fracture in the past 30 days [34]. Multimorbidity was defined as the presence of two or more chronic diseases [35].

Sample size

All data available from this sample were used to maximise the power of the results. To ensure accurate prediction in subsequent subjects, 2 to 20 subjects per predictor are required [36–38]. Our sample exceeds these minimum sample size requirements and is therefore expected to provide robust estimates.

Statistical analysis

Data from Belgium were excluded from analyses as information on informal care hours was not available (n = 525). Also, data from 224 Dutch respondents were excluded because data collection of interRAI-HC was put on hold in one Dutch organisation due to a software switch.

Socio-demographic and clinical characteristics at baseline were described using descriptive statistics and frequencies. Differences in baseline characteristics on country level were evaluated using Chi-square tests and ANOVAs.A histogram and a Normal Quantile plot were used to visually check the normality of societal costs. Log-transformation was used to account for skewness of the outcome measure. Distributions of all potential predictors were investigated using frequencies, descriptive statistics, boxplots and histograms. Also, normality of the distribution of regression residuals was checked [39].

Imputation of missing cost data was performed using Multivariate Imputation by Chained Equations (MICE) [40], stratified for country to increase the validity of the imputation. Predictive mean matching was used during imputation to account for the skewed distribution of costs [41]. For participants who passed away, costs were set at zero after death. Costs of institutionalised care for participants who were admitted between baseline and follow-up were assumed to be equal to the standard cost per admission day in a nursing home. These events were assumed to have taken place halfway between two assessments. Characteristics included in the multiple imputation model were baseline characteristics that differed significantly between participants and drop-outs, and baseline characteristics that were significantly associated with costs after six months. Ten imputed datasets were generated and separately analysed. The results were pooled using Rubin's rules [42].

Correlations between potential predictors were investigated using Pearson correlation coefficients. In case of collinearity ($r>0.8$), only the strongest associated variable was retained in the analysis [43]. Although common, univariable linear regression analyses to preselect predictors were not performed, since

important predictors may be rejected using this approach owing to nuances in the dataset or because they are confounded by other predictors [44–46].

A Linear Mixed Model was developed with fixed effects for all predictors plus a random intercept for country effects. Predictors were removed stepwise until all variables showed a statistically significant association with the outcome ($p \leq 0.05$). In case one of the dummies of a categorical predictor variable showed no significant association with the outcome, and the other(s) did, a likelihood ratio test was performed to compare models with and without that predictor variable and to assess their fit [47]. The model with the best fit determined whether the predictor was in- or excluded.

Model validation

An internal-external validation procedure was performed, which enables optimal use of sample size and allows dealing with potential heterogeneity between different IBenC countries [48, 49]. Data from all countries, but the validation country were iteratively used to develop a prediction model. This model was then validated against the validation country sample. This process was repeated until every country had functioned as validation country. Relevant predictors from the multivariable analyses were entered in each development sample. Subsequently, the intercept and regression coefficients were extracted and combined to create a linear predictor function and used to calculate a linear predictor score for every respondent in the validation sample. Different scenarios were created to investigate consistent model performance when applied in another country sample that was not included during its development [48, 50].

The quality of the prediction model was expressed as the explained variance (R^2). Various R^2 were calculated: R^2 for each country and R^2 as proposed by Snijders and Bosker [51, 52] based on the multilevel model including all countries.

The predictive performance (i.e. the agreement between predicted costs and observed costs) was assessed with ratios of predicted costs divided by mean observed costs (E/O-ratios) and calibration curves. In an ideal situation, E/O-ratios are 1 and all points of the calibration curve lie on the 45-degree slope [44]. To take clustering into account, the predictive performance in individual countries (within-cluster performance) was assessed [53]. Predicted and observed costs were back transferred using the exponential function. To calculate the calibration plot, groups of deciles were created based on predicted costs. Subsequently, mean predicted and observed costs were calculated for each group and plotted in a single figure [54]. The calibration curve was estimated as best-fit straight line through the calibration plot points.

Model optimisation

A final validation step was model optimisation. For countries in which model performance was low, the following options were considered to improve the model: updating the intercept or removal of predictors with predictive importance that have heterogeneous effects across countries [48].

The intercept was re-estimated using an offset procedure via Generalized Linear Models with an identity link. First, the linear predictor scores were re-calculated without the intercept. Second, the intercept was estimated by adding the linear predictor (as offset) as only variable in the model in the validation sample.

To provide insight into heterogeneous predictor effects across countries, regression coefficients from relevant predictor variables were estimated by country by linear regression analyses and plotted in a single figure. Higher between-county variability in regression coefficients indicate more heterogeneity for that predictor [50].

Results

Study sample

A total of 2135 participants from the original IBenC sample (n = 2884) were included in the analyses. Excluded respondents were statistically significantly older than the included respondents.

Between the baseline and six-month follow up assessments 94 participants were admitted to a care facility, 78 deceased, 16 were discharged from home care, and 53 participants were lost to follow-up due to lack of interest or time (n = 16), or without reason (n = 37)).

Two-thirds of the participants in the study sample were female and the mean age was 83.0 years. Significant differences ($p < 0.001$) were found between countries in all baseline characteristics (Table 2).

Societal costs

Six-month societal costs per participant were on average €18,467 (SE = 332). The highest societal costs were found in Italy (€26,980 (SE = 644) per participant per six months), followed by the Netherlands (€19,353 (SE = 1,202), Germany (€17,402 (SE = 649) and Finland (€14,245 (SE = 587), and the lowest societal costs were found in Iceland (€13,622 (SE = 623) per participant per six months).

Multivariable analyses

The multivariable analyses showed that living alone, caregiver distress, ADL and iADL impairment, required level of care support, health instability, presence of pain, behavioural problems, urinary incontinence, and multimorbidity statistically significantly predicted six-months societal costs (Table 3).

Model validation

The total variance in six-month societal costs explained by the final model was 32%. For individual countries, the explained variance ranged from 19% for Italy, 25% for the Netherlands, 34% for Finland, 34% for Iceland to 36% for Germany.

Figure 1 shows the predicted and observed societal costs for the different countries. Visual inspection of these calibration plots indicates that the model performed well for Iceland, Finland, and Germany, but

poorly for The Netherlands and Italy. Overall, E/O-ratios (Figure 1) were smaller than 1 in all validation countries. Figure 2 provides an overview of between-country variability in regression coefficients between countries. The predictors ADL and multimorbidity showed substantial between-country variability.

Model optimisation

For the Netherlands, estimated costs were much lower than observed costs (E/O = 0.51). Also, mean estimated costs for the different groups of deciles in the calibration plot were clustered around €15,000 (Figure 1). Predictor effects for the Netherlands deviated from the other countries for the predictors living alone, presence of pain, multimorbidity (stronger effects) (Figure 2). Model performance was improved by updating its intercept from 8.55 to 8.90 (Figure 3), resulting in an E/O-ratio of 0.72.

The calibration plot for Italy showed that costs were underestimated for people with relatively low observed societal costs and overestimated for people with relatively high observed societal costs. This led to a reasonably well E/O-ratio. However, considering the low explained variance and the poor calibration, we updated the model by removing predictors with overall the highest heterogeneity (ADL and multimorbidity). The updated model performed better as shown by the calibration plot (Figure 3), although the E/O-ratio deteriorated (0.69). The explained variance of the updated model was 19%.

Discussion

In this study, predictors of six-month societal costs in a sample of older community care-recipients from five European countries included living alone, caregiver distress, ADL and iADL impairment, required level of formal and informal care support, health instability, presence of pain, behavioural problems, urinary incontinence, and multimorbidity. The final model performed satisfactory for Iceland, Finland and Germany, and sufficiently for the Netherlands and Italy after optimisation. For the latter two countries, optimal model performance was achieved by increasing the intercept (the Netherlands) and by removing predictors with high heterogeneity (Italy).

The initial model underestimated costs for the Netherlands. Dutch care-recipients received relatively more care compared to the other countries. Noteworthy, the average level of impairment in the Dutch sample was relatively low while having the highest societal costs after Italy. Across all country samples, the Italian sample experienced on average the highest functional impairments. In Italy disabled people tend to live in the community longer than in other countries, which may be the result of cultural factors and of policy. Also, older adults in Italy were highly supported by informal care and they used relatively little professional home care compared with older adults in the other countries under study [55]. Such factors were not included in this study, which might be an explanation for the poor initial model performance in Italy. Future studies could investigate whether adding cultural factors can further improve the prediction model.

We found rather heterogeneous effects in relationship of ADL impairment and societal costs. Resource allocation in home care differs across countries. Although assessment of ADL and IADL impairment were

key aspects for determining eligibility to receive home nursing care in all countries, in some countries, the availability of informal caregivers is also taken into account [55]. Consequently, individuals with the same level of need do not necessarily receive the same level and mix of care services across countries [55]. This may explain the heterogeneity to some extent.

The predictors caregiver distress, ADL and IADL impairment, health instability, presence of pain, behavioural problems, and urinary incontinence may be modifiable to a certain degree and could be targeted in interventions to prevent high societal costs. ADL and IADL impairment are frequently identified as being key predictors of societal costs across (multi)national samples, our results confirm this [11, 13, 15–17, 56]. Interventions could, for example, aim to enhance self-efficacy and adaptive coping [57]. Health instability was included as a risk score for negative outcomes such as mortality, hospitalisation, pain, caregiver distress, and poor self-rated health which are in turn related to resource utilisation and costs. Health instability relates to identifies conditions that require rapid action to prevent further deterioration and is therefore well suited to flag interventions [32]. Presence of pain, caregiver distress, behavioural problems, and urinary incontinencewere also associated with higher societal costs in other studies [13, 58, 59]. Also for these conditions, appropriate (psychosocial) interventions may reduce resource utilisation and costs [60, 61].

The other, non-modifiable predictors found in this study may be used by policymakers for optimal resource allocation. Living alone significantly predicted lower six-month societal costs; required level of care support and multimorbidity were associated with higher six-month societal costs, which is in line with previous research [13, 16, 58, 59, 62]. In our sample, participants who lived alone experienced less cognitive and functional impairments than participants who lived together (data not shown). This might explain the association between living alone and lower six-month societal costs to some extent. The measure for required level of care support was developed by the interRAI-group based on the case-mix classification system “Resource Utilization Groups III Home Care” [31, 63] and was shown to explain 33.7% of the variance in resource use in the home care setting [31]. Our findings confirm that the required level of care support is also a predictor of societal costs.

Most previously conducted studies focused on community-dwelling older adults with dementia, a subgroup from our sample. Our study adds to these findings by confirming that these factors are also predictive of societal costs in older community care-recipients and are not country-specific.

Only one earlier study on predictors of societal costs reported information on model performance [16]. In that study, a pooled R^2 of 37% for dementia care costs was found based on the predictors ADL impairment, multimorbidity and falls, which is slightly higher than the R^2 found in the present study (32%). However, no model validation was performed in that study, leaving its predictive performance uncertain.

Strengths and Limitations

Strengths of this study are the large multinational sample, and the use of random effects to account for heterogeneity across countries. Further, the approach of this study was similar to an individual participant data (IPD) meta-analysis, since the various countries in our dataset were treated as individual samples [48, 64]. Prediction models based on IPD meta-analysis may be more generalizable than prediction models based upon single samples since the inclusion of multiple study samples addresses a wider range of study populations and increases the variation in the characteristics of the included participants [50]. An advantage of our study over an IPD meta-analysis is that all data were collected at the same time in a population with similar inclusion and exclusion criteria. IPD meta-analysis also allows researchers to synthesize country-data to develop and validate a single prediction model. Another strength of the study is the internal-external validation procedure. This approach allows for optimal use of sample size and enabled us to deal with heterogeneity [48, 49]. Maximizing sample size leads to more robust predictions compared to the more traditional approach of randomly splitting the sample for development and validation [48]. We evaluated whether the prediction models had good prognostic performance in individual countries and updated the country-specific models if necessary. Further, all data (care-recipient characteristics and resource utilisation) could be collected by a single instrument that is widely implemented in routine care practice. Finally, costs were estimated from a societal perspective, including costs of health care, social care and informal care, thereby providing a comprehensive view of the total costs for society.

For the cost calculation, some assumptions were made, which can be considered a potential limitation of the study. In case of admission to a long term care institution or death, we assumed that it took place halfway between two measurements, which is common practice in health economic models [63]. Another potential limitation is that Dutch standard costs were used to value resource utilisation for all countries under study. By using this approach, cost estimates of the various countries do not reflect “actual” care costs per country. An advantage of this approach is that it enables a relative benchmark of resource utilisation across countries, eliminating differences caused by factors related to national contexts rather than resource utilisation, like wages. Further, 8% of the total societal cost estimates were missing, which is a limitation of the study. To minimize the impact of bias due to selective dropout, multiple imputation was used, which is currently the recommended approach to account for missingness [66]. Another limitation is that costs of daycare utilisation are not recorded with the interRAI-HC and therefore not taken into account in this study. Costs of daycare may be substantial amongst this group. Further, participants from Belgium were excluded from the analyses because information on informal care hours was not available. Belgian participants were on average older than the included sample. However, we expect that the effect on the results is limited since age was not a relevant predictor. Finally, for some countries, the study samples are not necessarily representative of the national community care population, as the general aim of IBenC required a diverse sample of care organisations [18]. However, dependency levels in our samples closely reflect previously reported dependency levels among home healthcare-recipients [67]. Therefore, we expect that the developed model will perform satisfactorily in future samples. The representativeness of the IBenC study sample is described in more detail elsewhere [18].

Implications

Our prediction model may support policymakers across Europe to better understand the drivers of societal costs for older adults receiving community care services. Potentially modifiable predictors may be targeted in interventions aimed at reducing costs. In addition, it may be used to optimise resource allocations for the countries under study. Despite substantial differences of countries' care systems, a validated cross-national set of key predictors could be identified. Especially for Finland, Iceland and Germany, the prediction model performed well.

Conclusion

In this study, we derived and validated a model to predict societal costs in a sample of older community care-recipients in five European countries. This model comprised the potentially modifiable predictors caregiver distress, ADL and IADL impairment, health instability, presence of pain, behavioural problems, and urinary incontinence. These may be targeted by interventions aiming to reduce costs. In addition, non-modifiable predictors were identified, including living alone, required level of care support, and multimorbidity. The model may be used by policymakers to optimise resource allocation.

Declarations

Ethics approval and consent to participate

The study was performed in accordance with the Declaration of Helsinki and was approved by relevant legal authorised medical ethical committees in the countries that participated in the IBenC project (Belgium, Finland, Germany, Iceland, Italy, and The Netherlands). Prior to the start of the assessments, written informed consent was obtained from the participants. When a participant was known to be cognitively impaired, informed consent from a close relative, legal representative or legal guardian on behalf of the participant was obtained.

Names and reference numbers:

Belgium: Commissie Medische Ethiek van de universitaire ziekenhuizen KU Leuven, reference number: ML10265

Finland: Tutkimuseettinen työryhmä (TuET), reference number: THL/796/6.02.01/2014

Germany: Ethikkommission des Institut für Psychologie und Arbeitswissenschaft (IPA) der TU - Berlin, reference number: GH_01_20131022

Iceland: Vísindasiðanefnd, reference number: 13–176-S1

Italy: Comitato Etico, reference number: 2365/14

The Netherlands: Medical Ethics Review Committee of the VU University Medical Center (METc VUmc), reference number: 2013.333

Consent for publication

Not applicable.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Competing interests

HR, VG, AD, and HH are members of interRAI. LL, JB and MH declare no competing interests.

Funding

The IBenC study is funded by the 7th Framework Programme of the European Commission (grant number 305912).

Authors' contributions

LL, MH, and HH designed the study. LL conducted the analyses and drafted the manuscript. All authors revised and approved the final manuscript.

Acknowledgements

We thank the care organisations and the respondents for their participation in this study and the (research) nurses for conducting the interviews.

References

[1] Lanzieri G. The Greying of the Baby Boomers. A Century-long View of Ageing in European Populations. 2011.

[2] Rechel B, Grundy E, Robine JM, Cylus J, Mackenbach JP, Knai C, et al. Ageing in the European Union. Lancet. 2013;381(9874):1312–22.

[3] Age Platform Europe. Healthy and active ageing—Empowering Older People. 2016.

[4] Kok L, Berden C, Sadiraj K. Costs and benefits of home care for the elderly versus residential care: a comparison using propensity scores. Eur J Health Econ. 2015;16(2):119–31.

[5] Colombo F, Llena-Nozal A, Mercier J, Tjadens F. Help Wanted? Providing and Paying for Long-Term Care. In: Studie OHP, editor.2011.

[6] De la Maisonneuve C, Oliveira Martins J. The future of health and long-term care spending. In: Studies OJE, editor.2014.

[7] Global Coalition on Aging. A Sustainable Solution For Europe's Elder Care Crisis. Available from: https://globalcoalitiononaging.com/wp-content/uploads/2018/06/RHBC_Report_ DIGITAL.pdf. Accessed: 2018–08–11.

[8] Genet N, Boerma WG, Kringos DS, Bouman A, Francke AL, Fagerstrom C, et al. Home care in Europe: a systematic literature review. BMC Health Serv Res. 2011;11:207.

[9]Eurostat. Healthcare personnel statistics - nursing and caring professionals. 2018. Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php/Healthcare_personnel_statistics_-_nursing_and_caring_professionals#Healthcare_personnel_.E2.80.94_nursing_professionals. Accessed: 2019–03–04.

[10]Broese van Groenou MI, Alice De Boer A. Providing informal care in a changing society. European Journal of Ageing. 2016;13:271–9.

[11]Leicht H, Konig HH, Stuhldreher N, Bachmann C, Bickel H, Fuchs A, et al. Predictors of costs in dementia in a longitudinal perspective. PloS one. 2013;8:e70018.

[12]Handels RL, Wolfs CA, Aalten P, Verhey FR, Severens JL. Determinants of care costs of patients with dementia or cognitive impairment. Alzheimer Dis Assoc Disord. 2013;27:30–6.

[13]Gustavsson A, Brinck P, Bergvall N, Kolasa K, Wimo A, Winblad B, et al. Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients. Alzheimers Dement. 2011;7(3):318–27

[14]Jonsson L, Eriksdotter Jonhagen M, Kilander L, Soininen H, Hallikainen M, Waldemar G, et al. Determinants of costs of care for patients with Alzheimer's disease. International journal of geriatric psychiatry. 2006;21:449–5

[15]Joling KJ, Schöpe J, van Hout HP, van Marwijk HW, van der Horst HE, Bosmans JE. Predictors of Societal Costs in Dementia Patients and Their Informal Caregivers: A Two-Year Prospective Cohort Study. Am J Geriatr Psychiatry.

[16]Dodel R, Belger M, Reed C, Wimo A, Jones RW, Happich M, et al. Determinants of societal costs in Alzheimer's disease: GERAS study baseline results. Alzheimers Dement 2015;11:933–45.

[17]Van Lier LI, van der Roest HG, Oosten BS, Garms-Homolová V, Onder G, Finne-Soveri H, et al. Predictors of Societal Costs of Older Care-Dependent Adults Living in the Community in 11 European Countries. Health Serv Insights. 2019;12:1–13.

[18]Van der Roest, HG, van Eenoo L, van Lier LI, Onder G, Garms-Homolová V, Smit JH, et al. Development of a novel benchmark method to identify and characterize best practices in home care across six European countries: design, baseline, and rationale of the IBenC project outcomes of community care. BMC Health Serv Res. 2019;19:310

[19]InterRAI group. Licensing with interRAI. 2017. Available from: http://www.interrai.org/licensing.html. Last accessed: 2018–03–06.

[20]Hirdes JP, Ljunggren G, Morris JN, Frijters DH, Finne SH, Gray L, et al. Reliability of the interRAI suite of assessment instruments: a 12-country study of an integrated health information system. BMC Health Serv Res. 2008

[21]Landi F, Tua E, Onder G, Carrara B, Sgadari A, Rinaldi C, et al. Minimum data set for home care: a valid instrument to assess frail older people living in the community. Med Care. 2000;38(12):1184–90.

[22]Morris JN, Fries BE, Steel K, Ikegami N, Bernabei R, Carpenter GI, et al. Comprehensive clinical assessment in community setting: applicability of the MDS-HC. J Am Geriatr Soc. 1997;45:1017–24.

[23]OECD. Statistics Length of hospital stay Acute Care, days. 2016.

[24]Hakkaart-van Roijen L, van der Linden N, Bouwmans C, Kanters T, Swan Tan S. Kostenhandleiding: methodologie van kostenonderzoek en referentieprijzen voor economische evaluaties in de gezondheidzorg. 2015.

[25]van Lier LI, van der Roest HG, van Hout HP, Van EL, Declercq A, Garms-Homolova V, et al. Convergent validity of the interRAI-HC for societal costs estimates in comparison with the RUD Lite instrument in community dwelling

[26]Wimo A, Wetterholm AL, Mastey V, Winblad B. Evaluation of the resource utilization and caregiver time in Anti-dementia drug trials—a quantitative battery. The Health Economics of Dementia. London: Wiley; 1998. p. 465–99.

[27]Morris JN, Fries BE, Morris SA. Scaling ADLs within the MDS. J Gerontol A Biol Sci Med Sci. 1999;54:M546-M53.

[28]InterRAI group. Scales: Status and Outcome Measures. 2017.

[29]Morris JN, Fries BE, Mehr DR, Hawes C, Phillips C, Mor V, et al. MDS Cognitive Performance Scale. J Gerontol. 1994;49:M174-M82.

[30]Burrows AB, Morris JN, Simon SE, Hirdes JP, Phillips C. Development of a minimum data set-based depression rating scale for use in nursing homes. Age Ageing. 2000;29(2):165–72.

[31]Poss JW, Hirdes JP, Fries BE, McKillop I, Chase M. Validation of Resource Utilization Groups version III for Home Care (RUG-III/HC): evidence from a Canadian home care jurisdiction. Med Care. 2008;46(4):380–7.

[32]Hirdes JP, Frijters DH, Teare GF. The MDS-CHESS scale: a new measure to predict mortality in institutionalized older people. J Am Geriatr Soc. 2003;51(1):96–100.

[33]Fries BE, Simon SE, Morris JN, Flodstrom C, Bookstein FL. Pain in U.S. Nursing Homes: Validating a Pain Scale for the Minimum Data Set. Gerontologist. 2001;41:173–79.

[34]Foebel AD, Hirdes JP, Heckman GA, Kergoat MJ, Patten S, Marrie RA. Diagnostic data for neurological conditions in interRAI assessments in home care, nursing home and mental health care settings: a validity study. BMC Health Serv Res

[35]Calderón-Larrañaga A, Vetrano DL, Onder G, Gimeno-Feliu LA, Coscollar-Santaliestra C, Carfí A, et al. Assessing and Measuring Chronic Multimorbidity in the Older Population: A Proposal for Its Operationalization. J Gerontol A Biol Sci Med Sci. 2017 Oct; 72(10): 1417–1423.

[36]Green S. How many subjects does it take to do a regression analysis. Multivariate Behav Res. 1991;26:499–510.

[37]Harrell FE. Regression Modeling Strategies: With Applications to Linear Models, Logistic Regression and Survival Analysis. New York: Springer; 2001.

[38]Austin PC, Steyerberg EW. The number of subjects per variable required in linear regression analyses. Journal of Clinical Epidemiology. 2015;68:627–36.

[39]Twisk JWR. Inleiding in de toegepaste biostatistiek. 3 ed. Amsterdam: Reed Business Education; 2014.

[40]van Buuren S. Flexible Imputation of Missing data. New York: Chapman & Hall/CRC; 2012.

[41]Rubin DB. Statistical matching using file concatenation with adjusted weights and multiple imputations. Journal of Business & Economic Statistics. 1986;4:87–94.

[42]Rubin DB. Inference and Missing Data. Biometrika. 1976;62:581–90.

[43]Franke GR. Multicollinearity. John Wiley & Sons Ltd; 2010.

[44]Moons KGM, Altman DG, Reitsma JB, Ioannidis JPA, Macaskill P, Steyerberg EW, et al. Transparent Reporting of a multivariable prediction model for Individual Prognosis Or Diagnosis (TRIPOD): Explanation and Elaboration. Ann

[45]Steyerberg EW. Clinical Prediction Models: A Practical Approach to Development, Validation, and Updating. New York: Springer; 2009.

[46]Sun GW, Shook TL, Kay GL. Inappropriate use of bivariable analysis to screen risk factors for use in multivariable analysis. J Clin Epidemiol. 1996;49:907–16.

[47]Mistler SA. A SAS® Macro for Computing Pooled Likelihood Ratio Tests with Multiply Imputed Data. In: Forum SGW, editor.2013.

[48]Debray TPA, Riley RD, Rovers MM, Reitsma JB, Moons KGM, group CIM-aM. Individual Participant Data (IPD) Meta-analyses of Diagnostic and Prognostic Modeling Studies: Guidance on Their Use. PLos Med. 2015;12:e1001886.

[49]Steyerberg EW, Bleeker SE, Moll HA, Grobbee DE, Moons KG. Internal and external validation of predictive models: a simulation study of bias and precision in small samples. J Clin Epidemiol 2003;56:441–7.

[50]Debray TPA, Moons KGM, Ahmed I, Koffijberg H, Riley RD. A framework for developing, implementing, and evaluating clinical prediction models in an individual participant data meta-analysis. Statist Med. 2013;32:3158–80.

[51]Snijders TAB, Bosker RJ. Modeled Variance in Two-Level Models. Sociological Methods & Research. 1994;22:342–63.

[52]Snijders TAB, Bosker RJ. Multilevel Analysis. An Introduction to Basic and Advanced Multilevel Modeling. London: Sage; 1999.

[53]Bouwmeester W, Twisk J, Kappen T, van Klei W, Moons K, Vergouwe Y. Prediction models for clustered data: comparison of a random intercept and standard regression model. BMC Medical Research Methodology. 2013;13.

[54]Harrell FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors.. Statistics in Medicine. 1996;15:361–87.

[55]Van Eenoo L, Declercq A, Onder G, Finne-Soveri H, Garms-Homolová, Jónsson PV, et al. Substantial between-country differences in organising community care for older people in Europe - a review. Eur J Public Health. 2016;26(2):213–9.

[56]Gillespie P, O'Shea E, Cullinan J, Lacey L, Gallagher D, Ni Mhaolain A. The effects of dependence and function on costs of care for Alzheimer's disease and mild cognitive impairment in Ireland. Int J Geriatr Psychiatry. 2013;28(3):256–64.

[57]Gitlin LN, Winter L, Dennis MP, Corcoran M, Schinfeld S, Hauck WW. A Randomized Trial of a Multicomponenet Home Intervention to Reduce Functional Difficulties in Older Adults. JAGS. 2016;54:809–816.

[58]Dueñas M, Ojeda B, Salazar A, Mico JA, Failde I. A review of chronic pain impact on patients, their social environment and the health care system. J Pain Res. 2016;9:457–67.

[59]Zhu CW, Torgan R, Scarmeas N. Home health and informal care utilization and costs over time in Alzheimer's disease. Home Health Care Serv Q. 2008;27:1–20.

[60] Van Mierlo LD, Van der Roest HG, Meiland FJ, Dröes RM. Personalized dementia care: proven effectiveness of psychosocial interventions in subgroups. Ageing Res Rev. 2010 Apr;9(2):163–83.

[61] Stenzelius K, Molander U, Odeberg J, Hammarström M, Franzen K, Midlöv P, et al. The effect of conservative treatment of urinary incontinence among older and frail older people: a systematic review. Age Ageing. 2015 Sep;44(5):736–44.

[60]Picco L, Achilla E, Abdin E, Chong SA, Vaingankar JA, McCrone P, et al. Economic burden of multimorbidity among olders adults: impact on healthcare and societal costs. BMC Health Serv Res. 2016;16:703.

[61]Björkgren MA, Fries BE, Shugarman LR. A RUG-III case-Mix system for home care. Can J Aging. 2000;106–25.

[62]Riley RD, Lambert PC, Abo-Zaid G. Meta-analysis of individual participant data: rationale, conduct, and reporting. British Medical Journal. 2010:340:c221.

[63]Naimark DM, Bott M, Krahn M. The half-cycle correction explained: two alternative pedagogical approaches. Medical Decision Making. 2008;28:706–12.

[64]Oostenbrink JB, Al MJ. The analysis of incomplete cost data due to dropout. Health Econ. 2005;14:763–76.

[65]Carpenter I, Gambassi G, Topinkova E, Schroll M, Finne-Soveri H, Henrard JC, et al. Community care in Europe. The Aged in Home Care project (AdHOC). Aging Clin Exp Res. 2004;16:259–69.

Tables

Table 1. Overview of used unit cost (in € 2015) and average length of stay (days)

Care service	Costs [24]	Recall period	Extrapolation
Community care			
Home health aide (per hour)	€50	7 days	*13
Home nursing (per hour)	€73	7 days	*13
Physician visits			
General practitioner visit / Outpatient clinic visit (per visit)	€92	90 days	*1
Other healthcare services			
Physical therapy (per session)	€33	7 days	*13
Occupational therapy (per session)	€34	7 days	*13
Social worker (per session)	€64	7 days	*13
Hospital admissions			
Hospital admission with overnight stay (per day with overnight stay)	€479	90 days	*1
Average length of hospital stay [23]			
Finland	11.0 days	NA	
Germany	9.2 days	NA	
Iceland	5.8 days	NA	
Italy	7.7 days	NA	
Netherlands	5.2 days	NA	
Emergency room visit without overnight stay (per visit)	€261	90 days	*1
Supportive care services			
Home making services (per hour)	€23	7 days	*13
Meals on wheels (per day)	€7.50	7 days	*13
Institutionalized care			
Nursing home (per day)	€168	NA	
Informal care			
Informal care (per hour)	€14.08	3 days	/3*90

NA = not applicable

Table 2. Characteristics of the study population per country and of the total sample.

Variables	Total (n=2135)	Italy (n=499)	The Netherlands (n=267)	Iceland (n=420)	Finland (n=456)	Germany (n=493)	chi^2 / F	P value
Socio-demographics								
Country of residence, n (%)	Italy 499 (23%) Netherlands 267 (13%) Iceland 420 (20%) Finland 456 (21%) Germany 493 (23%)							
Mean age (SD)	83 (7.5)	81.8 (7.9)	82 (7.5)	83.7 (7)	82.9 (7)	84.2 (7.6)	8.3	< 0.001
Female, n (%)	1434 (67%)	286 (57%)	192 (72%)	292 (70%)	313 (69%)	351 (71%)	29.8	< 0.001
Living alone, n (%)	1259 (59%)	82 (16%)	193 (72%)	256 (61%)	369 (81%)	359 (73%)	523.3	< 0.001
Loneliness, n (%)	484 (23%)	43 (9%)	98 (37%)	85 (20%)	120 (26%)	138 (28%)	94.6	< 0.001
Caregiver distress, n (%)	278 (15%)	76 (15%)	22 (8%)	134 (32%)	22 (6%)	24 (8%)	141.3	< 0.001
Functional limitations								
Mild impairment (ADLH < 2), n (%) 702 (33%) Limited to extensive impairment (ADLH 2-4), n (%) 292 (14%) Dependent in ADLs (ADLH ≥ 5), n (%)	1141 (53%)	54 (11%) 237 (47%) 208 (42%)	221 (83%) 38 (14%) 8 (3%)	341 (81%) 77 (18%) 2 (1%)	359 (79%) 85 (19%) 12 (3%)	166 (34%) 265 (54%) 62 (13%)	947,9	< 0.001
Mean iADLCH score (SD)	3.9 (1.8)	5.1 (1.4)	2.7 (1.7)	3.5 (1.5)	3.9 (1.5)	3.8 (2.1)	103.1	< 0.001
Cognitive impairment (CPS ≥ 3), n (%)	407 (19%)	179 (37%)	4 (1%)	40 (10%)	49 (11%)	135 (27%)	221,1	< 0.001
Depressive symptoms (DRS ≥ 3), n (%)	303 (14%)	73 (15%)	54 (20%)	47 (11%)	37 (8%)	92 (19%)	33.1	< 0.001
Mean Case Mix Index, informal care (SD)	1.1 (0.7)	1.8 (0.7)	0.7 (0.4)	0.7 (0.5)	0.8 (0.5)	1.2 (0.7)	259.8	< 0.001
Mean CHESS score (health instability) (SD)	1.1 (1.1)	1.6 (1.3)	1.0 (1.0)	1.2 (1.0)	0.7 (0.9)	0.6 (0.9)	78.6	< 0.001
Presence of pain (Pain Scale > 0), n (%)	1085 (51%)	217 (43%)	126 (47%)	252 (60%)	277 (61%)	213 (43%)	55.9	< 0.001
Behavioural problems, n (%)	344 (16%)	65 (13%)	31 (12%)	42 (10%)	73 (16%)	133 (27%)	62.2	< 0.001
Any falls, n (%)	472 (22%)	156 (31%)	72 (27%)	80 (19%)	98 (21%)	66 (13%)	52.1	< 0.001
Clinical conditions								
Anxiety, n (%)	198 (9%)	51 (10%)	7 (3%)	120 (29%)	14 (3%)	6 (1%)	258.7	< 0.001
Dehydrated, n (%)	69 (3%)	26 (5%)	15 (6%)	6 (1%)	6 (1%)	16 (3%)	20.8	< 0.001

Dizziness, n (%)	860 (40%)	230 (46%)	111 (42%)	197 (47%)	178 (39%)	144 (29%)	40.3	< 0.001
Major skin problems or skin tears or cuts, n (%)	159 (7%)	76 (15%)	16 (6%)	12 (3%)	24 (5%)	31 (6%)	61.6	< 0.001
Any stasis ulcer, n (%)	196 (9%)	153 (31%)	5 (2%)	10 (2%)	10 (2%)	18 (4%)	361.3	< 0.001
Unintended weight loss, n (%)	196 (9%)	107 (21%)	28 (10%)	16 (4%)	7 (2%)	38 (8%)	138.3	< 0.001
Urinary incontinence, n (%)	1063 (50%)	326 (66%)	124 (47%)	182 (43%)	181 (40%)	250 (51%)	76.2	< 0.001
Diseases/disorders								
Alzheimer’s Disease, n (%)	260 (12%)	37 (7%)	9 (3%)	36 (9%)	143 (31%)	35 (7%)	203.3	< 0.001
Dementia other than Alzheimer, n (%)	346 (16%)	93 (19%)	7 (3%)	53 (13%)	46 (10%)	147 (30%)	123.5	< 0.001
Cancer, n (%)	273 (13%)	81 (16%)	48 (18%)	48 (11%)	42 (9%)	54 (11%)	19.0	< 0.001
COPD, n (%)	234 (11%)	73 (15%)	48 (18%)	64 (15%)	24 (5%)	25 (5%)	60.6	< 0.001
Congestive heart failure, n (%)	486 (23%)	103 (21%)	75 (28%)	128 (30%)	101 (22%)	79 (16%)	32.2	< 0.001
Coronary artery disease, n (%)	557 (26%)	128 (26%)	41 (15%)	168 (40%)	147 (32%)	73 (15%)	98.8	< 0.001
Diagnosis of urinary tract infection, n (%)	170 (8%)	53 (11%)	40 (15%)	36 (9%)	32 (7%)	9 (2%)	48.9	< 0.001
Depression, n (%)	286 (13%)	52 (10%)	29 (11%)	100 (24%)	36 (8%)	69 (14%)	56.6	< 0.001
Diabetes, n (%)	561 (26%)	129 (26%)	74 (28%)	61 (15%)	142 (31%)	155 (32%)	43.1	< 0.001
Hemiplegia, n (%)	111 (5%)	48 (10%)	7 (3%)	7 (2%)	20 (4%)	29 (6%)	35.1	< 0.001
Multiple sclerosis, n (%)	17 (1%)	6 (1%)	7 (3%)	3 (1%)	0 (0%)	1 (0%)	18.2	< 0.001
Parkinson’s disease, n (%)	150 (7%)	56 (11%)	18 (7%)	23 (5%)	22 (5%)	31 (6%)	18.8	< 0.001
Pneumonia, n (%)	85 (4%)	25 (5%)	22 (8%)	24 (6%)	7 (2%)	7 (1%)	32.8	< 0.001
Stroke (CVA), n (%)	271 (13%)	65 (13%)	45 (17%)	41 (10%)	55 (12%)	65 (13%)	7.8	< 0.001
Any fracture during last 30 days, n (%)	87 (4%)	46 (9%)	10 (4%)	9 (2%)	11 (2%)	11 (2%)	45.4	< 0.001
Multimorbidity (presence of two or more disease diagnosis), n (%)	1202 (56%)	293 (59%)	139 (52%)	278 (66%)	256 (56%)	236 (48%)	34.1	< 0.001

P-value < 0.05 indicates statistically significant differences between participants between countries. ADLH = Activities of Daily Living Hierarchy Scale; iADLCH = Instrumental ADL Capacity Hierarchy Scale; CHESS = Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; COPD = Chronic obstructive pulmonary disease; CPS = Cognitive Performance Scale; DRS = Depression Rating Scale; SD = standard deviation; chi^2 / F = test statistics Chi-square tests and ANOVAs.

Table 3. Results of the Linear Mixed Model analyses with fixed effects for the predictors plus a random intercept for the effects of country.

Predictor	β (95% CI)	P-value
Living alone (item 0-1)	-0.18 (-0.26; -0.11)	< 0.001
Caregiver distress (item 0-1)	0.15 (0.05; 0.25)	< 0.001
ADLH (limited to extensive ADL assistance (ADLH score 2-4) versus ADL independent (ADLH score 0-1))	0.21 (0.11; 0.3)	< 0.001
ADLH (ADL dependent (ADLH score 5-6) versus ADL independent (ADLH score 0-1))	0.28 (0.13; 0.43)	< 0.001
iADL (IADLCH, scale 0-6)	0.12 (0.09; 0.14)	< 0.001
Required level of care support (CMI informal care, 0.23 - 8.97)	0.19 (0.12; 0.27)	< 0.001
Health instability (CHESS, scale 0-6)	0.05 (0.02; 0.08)	< 0.001
Presence of pain (Pain Scale, item 0-1)	0.08 (0.02; 0.15)	0.01
Behavioural problems (item 0-1)	0.11 (0.02; 0.2)	0.01
Urinary incontinence (item 0-1)	0.1 (0.03; 0.17)	0.01
Multimorbidity (item 0-1)	0.09 (0.02; 0.15)	0.01
Intercept	8.61 (8.43; 8.79)	< 0.001
Random-effects Parameters		
Random intercept for country	**Estimate (SE)**	
sd(Intercept)	0.1472 (0.0512)	
sd(Residual)	0.7052 (0.012)	

Predictors that a showed statistically significant association with the outcome are included (cut-off point p = 0.05). β = regression coefficient; SE = Standard Error; sd = standard deviation; ADL = Activities of Daily Living; CHESS = Changes in Health, End-Stage Disease, Signs, and Symptoms Scale; iADL = Instrumental ADL; IADLCH = Instrumental ADL Capacity Hierarchy Scale

Figures



Figure 1

Graphical representation of predicted and observed societal costs E/O = ratio of predicted and observed costs. Solid line indicates the 45 degree line. Dotted line is the calibration curve (best fit of datapoints).



Figure 2

Heterogeneity among predictors included in the final multivariable model. Predictors are ordered based on their variability between countries (low to high).



Figure 3

Model optimisation for the Netherlands and Italy. Solid line indicates the 45 degree line. Dotted line is the calibration curve (best fit of datapoints)

Supplementary Files

This is a list of supplementary files associated with this preprint. Click to download.

- PredictorsSupmaterialSep2019.docx